Private Equity Backers Of Plan B Morning-after Pill Weigh $4B Sale Of Company
Portfolio Pulse from Benzinga Newsdesk
The private equity backers of the Plan B morning-after pill are considering a sale of the company, potentially valued at $4 billion, according to Bloomberg. Corcept Therapeutics (CORT) is mentioned in the article.
July 26, 2023 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Corcept Therapeutics is mentioned in the context of a potential $4 billion sale of the company behind the Plan B pill. The impact on CORT is unclear without further details.
The article mentions Corcept Therapeutics in relation to a potential sale of the company behind the Plan B pill. However, without further details, it's unclear what the impact on CORT's stock might be.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50